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ABSTRACT  
Background: The number of patients with diabetes mellitus (DM) presenting with coronary 
artery disease is increasing and accounts for more than 30% of patients undergoing 
percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents 
were developed to improve vascular healing. It was sought herein, to determine 1-year 
clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-
coated sirolimus-eluting (BP-SES) stent versus durable coating everolimus-eluting stent (DP-
EES). 
Methods: Patients were retrospectively analyzed with DM were treated with either a BP-SES 
(ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884) with 
available 1 year clinical follow-up using propensity score matching. Outcomes included target 
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vessel revascularization (TVR) as efficacy outcome and all-cause death, myocardial 
infarction, and definite/probable stent thrombosis as safety outcomes. 
Results: After propensity score matching 527 patients treated with BP-SES and 527 patients 
treated with DP-EES were selected. Procedural and clinical characteristics were similar 
between both groups. In-hospital mortality was 3.23% in BP-SES vs. 2.09% in DP-EES group 
(p = 0.25). One-year follow-up demonstrated comparable efficacy outcome TVR (BP-SES 
6.64% vs. DP-EES 5.88%; p = 0.611), as well as similar safety outcomes of all-cause death 
(BP-SES 10.06% vs. DP-EES 7.59%; p = 0.158), myocardial infarction (BP-SES 7.959% vs. 
6.83%; p = 0.813), and definite/probable stent thrombosis (BP-SES 1.14% vs. DP-EES 
0.76%; p = 0.525). 
Conclusions: The thin-strut biodegradable polymer coated, sirolimus-eluting stent 
demonstrated comparable clinical outcomes at 1-year after implantation to DP-EES. These 
data support the relative safety and efficacy of BP-SES in diabetic patients undergoing PCI. 
Key words: drug-eluting stents, percutaneous coronary intervention, diabetes mellitus 
 
 
Introduction 
The number of patients with diabetes mellitus (DM) presenting with coronary artery 
disease (CAD) is increasing and accounts for more than 30% of patients undergoing 
percutaneous coronary interventions (PCI) [1]. The pathophysiology associated with diabetic 
vasculopathy is multifactorial and includes endothelial dysfunction, non-enzymatic glycation 
end products, circulating free fatty acids, increased systemic inflammation, diabetic 
autonomic neuropathy, and the vascular effects of hyperinsulinemia [2, 3]. Randomized 
clinical trials, have demonstrated higher efficacy of coronary artery bypass grafting (CABG) 
when compared with PCI in DM population especially in patients with multivessel disease 
and complex coronary anatomy [4]. Nevertheless, advances in the drug eluting stents (DES) 
technology, have made stents a viable and less invasive alternative therapy when compared to 
CABG for patients with less complex anatomy. Second-generation DES reduced rates of stent 
thrombosis (ST) with preserved low restenosis rates when compared to first-generation DES 
[5–7]. However, very late ST and neoatherosclerosis have been recently observed also with 
second-generation DES [8–10]. To address the limitations of the durable polymer DES, new 
platforms that make use of biodegradable polymers have been developed. The safety and 
effectiveness of biodegradable polymer coated DES (BP-DES) over first-generation DES has 
been previously demonstrated in reducing the risk of very late ST and restenosis [11–13]. 
 3 
However, patients with DM constitute a challenging subset, with poorer outcomes after PCI 
in comparison with non-diabetics. These patients often present with unfavorable coronary 
anatomy with small and diffusely diseased vessels and multi-vessel involvement [14].  
In the present study, it was sought to determine the 1-year clinical follow-up of 
patients treated with the thin strut BP-coated sirolimus-eluting stent (BP-SES) versus durable 
coating everolimus-eluting stent (DP-EES) in an all-comers DM population.  
 
Methods 
Study design 
 The interventional cardiology network registry is a prospective, observational registry 
which includes all patients treated with PCI in 4 Polish interventional cardiology centers in 
Poland. A retrospective screening of unselected patients (n = 21,400) treated with PCI between 
2010 and 2016 was undertaken. All consecutive patients included  were previously diagnosed 
with DM who underwent single or multi-vessel revascularization with either BP-SES (ALEX, 
Balton, Warsaw, Poland) or DP-EES (XIENCE, Abbott Vascular, Santa Clara, CA) during the 
index procedure following acute coronary syndrome or stable angina presentation. Follow-up 
data for patients treated in years 2015–2016 is currently not available. Therefore, for final 
analysis only patients treated between 2010 and 2014 were selected, due to availability of 1-
year follow-up data for all the patients. Due to observational nature of the study and lack of 
any interference in diagnostic and therapeutic decision-making process no permission was 
required from the Institutional Review Board and Bioethics Committee. 
 
Stent system description  
 The BP-SES used in this study is a Conformité Européenne (CE)-approved balloon 
expandable cobalt-chromium stent with a 71 microns strut thickness covered with a 
biodegradable copolymer of poly-lactic and glycolic acid together with sirolimus. In a 
previously published study, BP-SES demonstrated comparable safety and efficacy in all-
comers and acute myocardial infarction patient population when compared to the benchmark 
balloon-expandable cobalt-chromium DP-EES [15, 16]. DP-EES was previously granted the 
specific indication for DM patients from the Food and Drug Administration of the United 
States and CE mark from the European Commission. DP-EES has a strut thickness of 81 
microns. Everolimus is blended in a non-erodible polymer coated over another non-erodible 
polymer primer layer.  
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Study population 
 The demographic, clinical and angiographic data collected in the course of the index 
hospitalization were retrieved from a prospectively recorded Institutional Electronic Database. 
Follow-up data, including exact dates of death, myocardial infarction (MI) and repeat 
revascularization were obtained from the health insurer (National Health Fund) database. 
Detailed angiographic data for repeat revascularization were obtained from the medical centers 
that performed the procedures.  
 All patients underwent coronary angiography with following or postponed PCI using 
standard devices. All interventional strategies, including the use of stents, choice of stent type 
and periprocedural antithrombin and antiplatelet therapy, were at the discretion of the 
attending physicians. Pharmacological treatments recommended by the European Society of 
Cardiology were introduced before and after the intervention unless contraindicated.  
 
Definitions and endpoints 
 The efficacy outcome was defined as target vessel revascularization (TVR). The safety 
outcomes included separate endpoints of death, MI, and definite or probable ST. MI was 
defined as an ischemic event that fulfilled the European Society of Cardiology/American 
College of Cardiology criteria for MI and was clinically distinct from the index event at the 
time of first hospitalization [17]. TVR was defined as any repeat percutaneous intervention or 
surgical bypass of any segment of the target vessel including ischemia-driven and 
symptomatic-driven intervention. ST was considered as acute (0–24 h), subacute (> 24 h to 30 
days) or late (> 31 days) and was defined as either definitive or probable according to the 
Academic Research Consortium [18]. 
 
Statistical analysis 
 Categorical variables are presented as percentages and were compared using the χ2 test, 
whereas continuous variables are displayed as means ± standard deviation and were compared 
using the Student t-test. A propensity score method was used to match the BP-SES and DP-
EES groups for all baseline clinical characteristics and angiographic parameters listed in 
Tables 1 and 2. The area under curve for logistic model was 0.708 (95% confidence interval 
0.686–0.731); p < 0.0001. The greedy matching algorithm, available in NCSS, was used with 
the distance calculation option set to “Mahalanobis Distance within Propensity Score Calipers 
(no matching outside caliper)” and caliper to 0.2*Sigma. Cumulative event rates in 1-year 
follow-up were analyzed with the Kaplan-Meier method and compared with the log-rank test. 
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All tests were 2-tailed, and a p-value < 0.05 was considered to indicate statistical significance. 
Statistics were calculated with STATISTICA 12 (Statsoft, Tulsa, Oklahoma, USA) and NCSS 
12 Statistical Software (NCSS, LLC. Kaysville, Utah, USA). 
 
Results 
Baseline demographic characteristics  
 A total of 670 BP-SES and 884 DP-EES patients were found to be eligible for 
matching. Patients in BP-SES group were older than in DP-EES group (respectively: 68.78 ± 
9.14 vs. 67.75 ± 9.60; p = 0.031). Previous MI and PCI procedures were less common in the 
BP-SES group when compared to DP-EES (respectively: 31.34% vs. 37.22%; p = 0.016, 
22.69% vs. 30.20%; p < 0.001). Cardiogenic shock at admission occurred more often in BP-
SES than in DP-EES group (respectively: 3.28% vs. 1.36%; p = 0.010) 
 Following propensity score analysis and matching, 527 pairs were selected for further 
analysis with a mean age of 68.41 ± 9.13 years in BP-SES group and 68.21 ± 9.34 in DP-EES 
group. There were no relevant differences found in baseline characteristics following 
matching. The proportions of patients with ST-segment elevation MI (BP-SES 10.63% vs. 
DP-EES 10.63%) and non-ST segment MI (BP-SES 30.17% vs. DP-EES 28.08%) unstable 
(BP-SES 38.9% vs. DP-EES 37.57%) and stable angina (BP-SES 24.29% vs. DP-EES 
23.52%) were comparable between matched groups. An overview of the unmatched and 
matched baseline characteristics is presented in Table 1. 
 
Patients angiographic and procedural characteristics 
 Before propensity score matching, there were significant differences between BP-SES 
and DP-EES in angiographic and procedural characteristics. Left main CAD occurred less 
frequently in the BP-SES group when compared to the DP-SES group. The rate of multi-
vessel PCI was lower in BP-DES compared to DP-EES. The proportion of direct stenting rate 
was similar in both studied groups. Also, number of stents implanted per patient was similar 
between the groups.  
 After propensity score matching angiographic and procedural characteristics such as a 
multi-vessel CAD, left main CAD and targeted vessels were comparable between studied 
groups. There was no difference in single-vessel intervention rates. There was no difference 
in the number and length of stents implanted per patient. Angiographic and procedural 
characteristics, before and after propensity score matching, are summarized in Table 2. 
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Clinical outcomes in matched cohorts 
 In-hospital (BP-SES 3.23% vs. DP-EES 2.09%; p = 0.250) and 30-day mortality (BP-
SES 4.55% vs. DP-EES 2.47%; p = 0.066) was comparable in the matched groups. The 
efficacy outcome of TVR rates at 12 months did not differ significantly between BP-SES and 
DP-EES (respectively: 6.64% vs. 5.88%; p = 0.611). There was also no difference in safety 
endpoints between the matched groups regarding death, MI, and definite/probable ST (Fig. 1). 
All-cause mortality at 1 year was similar in both groups (BP-SES 10.06% vs. DP-EES 7.59%; 
p = 0.158). MI rates were comparable in both groups (BP-SES 7.59% vs. DP-EES 6.83%; p = 
0.633). The cumulative rates of definite/probable ST were relatively low with no significant 
difference between the matched groups (BP-SES 2.66% vs. DP-SES 1.90%; p = 0.408). Also, 
there was no difference in acute (BP-SES 0.00% vs. DP-SES 0.19%; p = 0.317), subacute 
(BP-SES 1.52% vs. DP-SES 0.95%; p = 0.402) and late (BP-SES 1.14% vs. DP-SES 0.76%; 
p = 0.525) definite/probable ST. In summary, no significant differences were found in terms 
of clinical outcomes after 1 year. Detailed follow-up results are presented in Table 3. 
 
Discussion 
 The present study describes a direct comparison of the clinical outcomes of thin strut 
biodegradable polymer coated sirolimus-eluting stent against benchmark non-erodible 
polymer coated everolimus-eluting stent in the DM patients. The major finding of this 
investigation in a propensity-matched cohort is comparable 1-year clinical outcomes for the 
BP-SES when compared with DP-EES, with reasonable event rates, demonstrating similar 
safety and efficacy of the devices in the DM patient population.  
Coronary artery disease remains the most important cause of morbidity and mortality 
among patients with DM. It is estimated that 75% of patients with diabetes will die from 
cardiovascular causes [19]. DM patients often present with unfavorable coronary anatomy 
with small and diffusely diseased vessels and multi-vessel involvement when compared to 
non-diabetics [14]. Hyperglycemia and associated metabolic disarrangements enhance the 
development, progression, and instability of atherosclerotic plaque [2]. The diabetic 
vasculopathy pathophysiology is multifactorial and includes vascular effects of 
hyperinsulinemia, non-enzymatic glycation end products, endothelial dysfunction, circulating 
free fatty acids, diabetic autonomic neuropathy, and increased systemic inflammation [2]. 
Despite similar initial angioplasty success rates, DM patients have higher restenosis rates and 
worse long-term outcomes. Also, in a DM population, acute coronary syndrome is more 
frequent and has a higher risk of complications [20]. Although DES implantation reduces 
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neointimal hyperplasia and TVR rates in these patients, diabetes remains a risk factor for 
restenosis and adverse events after PCI [21, 22]. The increase in oxidative and inflammatory 
mediators in diabetic patients promotes atherosclerosis [19]. Rapamycin and its analogs (like 
sirolimus and everolimus) are mTOR complex inhibitor agents. In animal models, the 
enhancement of the extracellular signal response kinase (ERK) pathway produces a relative 
resistance to mTOR inhibitors. Therefore, the demonstration of an enhanced activity of the 
ERK pathway in diabetic vasculature provides an alternative pathway, not affected by limus 
analogues, for proliferation of vascular smooth muscle cells. This potentially explains the 
reduction in the long-term effectivity of limus eluting stents in DM [23]. 
Higher adverse events rate etiology in DM patients seems to be multifactorial and due 
to patient-related and stent-related causes [24]. In the present study, propensity matched 
analysis was performed, therefore most of the patients related variables were controlled and 
equally distributed. Regarding the possible stent-related causes there are different 
characteristics of tested devices that could impact outcomes between BP-SES and DP-EES, 
such as the thinner strut thickness (71 μm vs. 81 μm), the presence of biodegradable polymer, 
and the limus analogue used (sirolimus vs. everolimus). Although polymer provides a 
reservoir for programmed drug release, it has no function when drug release is completed, and 
it may affect late and very late safety and efficacy of DES. In fact, durable polymers may be 
associated with inflammation, neoatherosclerosis and incomplete stent endothelialization 
which may contribute to the risk of adverse events also observed with new durable polymers 
DES [25, 26]. However, recent reports demonstrated similar clinical outcomes after 
implantation of BP-DES when compared to second generation durable polymer coated stents 
despite their theoretical advantages. In a large meta-analysis, treatment with BP-DES 
significantly reduced late lumen loss and late stent thrombosis rates, without clear benefits on 
harder endpoints compared to durable polymer DP-DES [27]. Herein, it was speculated that, 
in the pro-inflammatory milieu typical of DM patients, the presence of biodegradable polymer 
and thinner struts could be important factors that could affect long-term outcomes after BP-
SES implantation when compared to DP-EES [28]. 
A previously published study demonstrated favorable safety and efficacy of DP-EES 
in a diabetic population [29]. Clinical events in the present study was numerically higher in 
the BP-SES group when compared to the DP-EES group, however the differences were not 
statically significant. Therefore, BP-SES demonstrated no-inferior outcomes to DP-EES in a 
diabetic population. There was no significant difference in TVR rates between the BP-SES 
and DP-EES groups (respectively: 6.64% vs. 5.88%; p = 0.611). The current study also 
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showed that treatment with BP-SES was not associated with significantly increased mortality 
(respectively: 10.06% vs. 7.59%; p = 0.158) and MI rates (respectively: 7.59% vs. 6.83%; p = 
0.634) when compared to DP-EES. Furthermore, no significant differences were found in 
terms of definite and probable stent thrombosis (BP-SES 2.66% vs. DP-SES 1.90%; p = 
0.408). The 12-month rates of ST found in this study are slightly higher than in randomized 
trials comparing biodegradable and durable polymer coated DES. However, it needs to be 
emphasized that the mentioned difference is probably attributed exclusively to a diabetic 
population and a high proportion of patients with acute coronary syndromes which are 
included in present study [30]. 
It has been previously postulated that longer follow-up is required to demonstrate risk 
reduction of adverse events in favor of BP-DES compared with DP-DES [31]. For example, 
5-year results in the LEADERS trial showed BP-DES was associated with a significant 
reduction in very late, (> 1 year), definite stent thrombosis [32]. Therefore, follow-up beyond 
1 year is required to clarify the potential benefit of BP-SES over DP-EES on clinical 
outcomes in the DM population. 
Taking into consideration the above observations, in a propensity-matched cohort, the 
opinion reached was that BP-SES included in the present study displays a similar efficacy 
profile as benchmark DP-EES, without compromising safety, which is of utmost importance 
among DM patients treated in routine clinical practice.  
 
Limitations of the study 
 First, the current study is limited by its observational nature and patients were not 
enrolled in a randomized fashion. Thus, any findings should be confirmed by prospective and 
sufficiently powered clinical trials. Nevertheless, more challenging patients are often 
excluded from randomized controlled trials. For such reasons, observational studies can be 
used as complementary forms of research in real-world populations [33]. An attempted to 
minimize the selection bias on whether to implant BP-SES or DP-EES by using a propensity 
score matching for a wide range of variables was undertaken. However, not all differences 
between the groups could be addressed. For example, matching by coronary lesion 
complexity according to the American College of Cardiology/American Heart Association 
classification was not performed. 
 Second, no routine angiographic surveillance was scheduled, and thus no conclusions 
regarding potential restenosis could be made. Also, no intravascular imaging data was 
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collected. Adequate DAPT is one of the most important factors preventing stent thrombosis. 
However,  data on antiplatelet drug compliance during follow-up was not available. 
 Third, only patients treated between 2010 and 2014 were evaluated due to lack of 
currently available follow-up for 546 patients treated in the years 2015–2016. 
 Fourth, optimal medical therapy could have impacted clinical outcomes, especially in 
terms of ST and cardiac death, but unfortunately no specific analysis was performed because 
data from therapy at follow-up was not available.  
 Finally, the present study is limited to 1 year of follow-up, while theoretical 
differential clinical outcomes between the compared technologies might have been observed 
during long-term follow-up.  
 
Conclusions 
 This is the first competitive evaluation of BP-SES vs. DP-EES in DM population. It 
provides evidence for the safety and efficacy of BP-SES. The 12-month outcomes for BP-SES 
were similar to DP-EES. These findings should be verified in a prospective, randomized trial.  
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Table 1. Baseline characteristics.  
 Unmatched Matched 
 BP-SES 
(n = 670) 
DP-EES 
(n = 884) 
P 
BP-SES 
(n = 527) 
DP-EES 
(n = 527) 
P 
Age [years] 68.78 ± 9.14 67.75 ± 9.60 0.031 68.41 ± 9.13 68.21 ± 9.34 0.711 
Female  49.10% 45.02% 0.110 47.06% 48.96% 0.538 
Previous MI  31.34% 37.22% 0.016 32.26% 34.91% 0.361 
Previous PCI  22.69% 30.20% 0.001 24.67% 26.19% 0.571 
Previous bypass surgery  10.30% 10.86% 0.722 10.06% 10.82% 0.687 
Previous stroke  5.82% 4.86% 0.403 4.93% 4.93% 1.000 
Hypertension  90.15% 89.48% 0.666 89.94% 89.75% 0.919 
Hypercholesterolemia 40.60% 42.76% 0.392 40.04% 42.31% 0.453 
Smoking  14.33% 11.65% 0.118 13.28% 13.09% 0.927 
Obesity  45.97% 44.34% 0.523 45.73% 45.35% 0.902 
Chronic heart failure  26.42% 26.58% 0.942 26.38% 27.51% 0.677 
Chronic renal failure  13.58% 14.14% 0.753 12.71% 12.33% 0.852 
Cardiogenic shock (%) 3.28% 1.36% 0.010 2.09% 1.71% 0.652 
Indication for procedure: 
STEMI 11.04% 9.05% 0.192 10.63% 10.63% 1.000 
NSTEMI 29.10% 11.04% 0.156 28.08% 30.17% 0.456 
Unstable angina 37.46% 37.22 0.921 38.90% 37.57% 0.657 
Stable CAD 23.30% 24.03% 0.738 24.29% 23.52% 0.773 
MI — myocardial infarction; STEMI — ST segment elevation myocardial infarction; NSTEMI — non-ST segment elevation myocardial 
infarction; CAD — coronary artery disease 
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Table 2. Angiographic and procedural characteristics. 
 Unmatched Matched 
 BP-SES  
(n = 670) 
DP-EES  
(n = 884) 
P 
BP-SES 
(n = 527) 
DP-EES 
(n = 527) 
P 
Multi-vessel CAD 66.87% 70.14% 0.169 66.22% 67.36% 0.695 
LM CAD 4.03% 7.13% 0.001 3.98% 3.98% 1.000 
Target vessel: 
LM 1.04% 5.88% < 0.001 1.33% 0.57% 0.204 
LAD 38.66% 51.36% < 0.001 42.31% 44.40% 0.494 
Cx 23.88% 12.56% < 0.001 19.76% 21.26% 0.490 
RCA 32.24% 26.92% 0.022 32.26% 29.79% 0.387 
Bypass 4.18% 3.28% 0.351 4.36% 3.98% 0.758 
Single vessel PCI 85.67% 77.04% < 0.001 85.01% 85.39% 0.543 
Bifurcation PCI 6.72% 17.53% < 0.001 7.40% 7.21% 0.906 
Stents used per patient 1.45 ± 0.82 1.46 ± 0.75 0.847 1.42 ± 0.77 1.41 ± 0.73 0.890 
Total length of stents  26.39 ± 16.94 30.61 ± 17.67 < 0.001 26.85 ± 16.75 26.84 ± 15.28 0.991 
Maximal implantation pressure 14.67 ± 2.23 14.64 ± 2.79 0.854 14.68 ± 2.24 14.64 ± 2.72 0.823 
Direct stent implantation 40.00% 35.52% 0.071 37.76% 38.33% 0.849 
Post dilatation  22.54% 23.08% 0.802 21.82% 18.79% 0.221 
Thrombectomy  4.18% 3.96% 0.828 3.23% 4.36% 0.333 
Procedural glycoprotein IIb/IIIa inhibitor  5.07% 5.54% 0.684 4.36% 4.36% 1.000 
CAD — coronary artery disease; LM — left main; LAD — left anterior descending; Cx — circumflex; RCA — right coronary artery; PCI — 
percutaneous coronary intervention 
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Table 3. Clinical outcomes at 30 days, 6 months, and 12 months in a propensity matched cohort. 
 BP-SES 
(n = 527)  
DP-EES 
(n = 527)  
P 
30 days 
Target vessel revascularization 6 (1.14%) 5 (0.95%) 0.762 
Myocardial infarction 9 (1.71%) 9 (1.71%) 1.000 
All cause death 24 (4.55%) 13 (2.47%) 0.066 
6 months 
Target vessel revascularization 26 (4.93%) 16 (3.04%) 0.115 
Myocardial infarction 26 (4.93%) 26 (4.93%) 1.000 
All cause death 37 (7.02%) 30 (5.69%) 0.377 
12 months 
Target vessel revascularization 35 (6.64%) 31 (5.88%) 0.611 
Myocardial infarction 40 (7.59%) 36 (6.83%) 0.633 
All cause death (n) 53 (10.06%) 40 (7.59%) 0.158 
Definite/probable stent thrombosis    
Acute (0–1 days) 0 (0.00%) 1 (0.19%) 0.317 
Subacute (2–30 days) 8 (1.52%) 5 (0.95%) 0.402 
Late (31–365 days) 6 (1.14%) 4 (0.76%) 0.525 
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Figure 1. One-year Kaplan-Meier events rates. Kaplan-Meier curves show the cumulative 
incidence of (A) target vessel revascularization; (B) myocardial infarction; (C) all-cause 
death; and (D) definite/probable stent thrombosis. 




